Industry Wire 214

September 27, 2024 Jake Fishman 0 min read
  1. LAPD officer’s gun sucked into MRI machine during raid.
  2. Dems introduce legislation to permanently lower ACA plan costs. 
  3. Cardinal Health acquires Integrated Oncology Network for $1B.
  4. CDC: 40.3% of U.S adults are obese, 46.5% of adults aged 40-59.
  5. VA’s new Oracle EHR saw 826 ‘major’ incidents since its launch.
  6. U.S. House committee passes rare pediatric disease drug bill.
  7. 29% of Americans have undiagnosed iron deficiency.
  8. Senate holds Steward Health CEO in criminal contempt.
  9. PA-based system fires workers for sharing inappropriate patient images.
  10. Providers say reimbursement denials are getting worse.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Pharmaceuticals November 24, 2025

Winrevair Shows Early HFpEF Win in CADENCE November 24, 2025

Winrevair (sotatercept-csrk) might become Merck’s next blockbuster after positive Phase 2 results from the CADENCE study showed it led to significant improvements in pulmonary blood flow in patients with precapillary pulmonary hypertension due to HFpEF. Focused on exploring Winrevair’s HF impact, the Phase 2 CADENCE study enrolled 164 adults with PAH caused by HFpEF, comparing […]

Structural Heart November 20, 2025

Meril’s Myval Makes its Mark With LANDMARK November 20, 2025

The TAVR race might be closer to having another competitor in North America, after the LANDMARK trial’s one-year results suggest that Meril’s Myval THV series achieved comparable clinical efficacy to both Edwards’ Sapien and Medtronic’s Evolut AVR systems. The LANDMARK trial enrolled 768 patients with symptomatic severe aortic stenosis at 31 sites across 16 countries, […]

Pink heart

Atrial Fibrillation November 17, 2025

CLOSURE-AF Results Question Just How Good LAAO Is November 17, 2025

There’s been some serious debate over the last few years about whether or not left atrial appendage occlusion is actually the best stroke prevention option for high-risk AFib patients, and the latest results from the CLOSURE-AF trial suggest it might not be as effective as previously thought. To bring closure to the LAAO debate, CLOSURE-AF […]